Central European Journal of Immunology is a premier publication dedicated to advancing the field of immunology and allergy research. Established in 1996 and published by TERMEDIA PUBLISHING HOUSE LTD, this open access journal has consistently provided a platform for innovative research and comprehensive reviews since its transition to open access in 2002. With an ISSN of 1426-3912 and E-ISSN of 1644-4124, it embraces a global readership while being rooted in Poland. The journal, with a notable Q3 ranking in both the categories of immunology and allergy in 2023, positions itself within the competitive landscape of scientific discourse, as reflected in its Scopus rankings. Designed for researchers, professionals, and students, the Central European Journal of Immunology not only disseminates significant findings but also fosters collaboration and innovation in the immunological sciences, making it a vital resource for those seeking to stay current in this rapidly evolving field.

BMC Immunology is a prominent open-access journal published by BMC that has been at the forefront of immunological research since its inception in 2000. Based in the United Kingdom, this journal aims to advance the understanding of immune system functions and disorders through high-quality, peer-reviewed articles. With an impressive scope encompassing various facets of immunology, BMC Immunology has earned a Q3 ranking in the Immunology category according to the 2023 category quartiles, demonstrating its growing impact and relevance in the scientific community. Researchers and professionals will find valuable insights in its array of published works, spanning both foundational studies and innovative applications. The journal's commitment to open access ensures that cutting-edge research is freely available, fostering collaboration and advancement in the field. For those looking to stay updated on the latest developments in immunology, BMC Immunology stands as an essential resource for researchers, professionals, and students alike.

Genes & Diseases, published by KEAI PUBLISHING LTD, is a premier open-access journal dedicated to advancing the fields of genetics, biochemistry, and molecular biology. Established in 2014 and headquartered in Beijing, China, this journal has quickly risen to prominence, securing a place in the prestigious Q1 quartile in Biochemistry and Genetics (clinical), as well as Q2 in Cell Biology and Q1 in Molecular Biology as of 2023. With a commitment to disseminating cutting-edge research, Genes & Diseases serves as a critical platform for researchers, professionals, and students alike, ensuring that high-quality scientific work is openly accessible to the global community. The journal's exceptional impact is underscored by its selective Scopus rankings, which reflect its influence and relevance in key scientific domains, making it an essential resource for those exploring the intersections of genetics and disease pathology.

HUMAN IMMUNOLOGY, published by Elsevier Science Inc, serves as a critical platform for disseminating research in the fields of immunology and allergy, as well as various aspects of miscellaneous medicine since its inception in 1980. With an ISSN of 0198-8859 and E-ISSN 1879-1166, this journal is pivotal for researchers and practitioners looking to advance their understanding of human immune responses and related conditions. The journal currently holds a respectable position within its field, as highlighted by its 2023 Scopus ranks—#114/233 in Immunology and Allergy and #132/236 in Immunology and Microbiology. Moreover, it maintains a Q2 quartile ranking in both Immunology and Allergy and miscellaneous Medicine, underscoring its influence and reach within the scientific community. Although it does not currently offer Open Access options, HUMAN IMMUNOLOGY remains dedicated to providing valuable insights and fostering academic discourse within its discipline, characterized by a rigorous peer-review process and a focus on innovative research trajectories.

OncoImmunology is a leading peer-reviewed journal published by Taylor & Francis Inc, dedicated to advancing the understanding of the dynamic interplay between the immune system and cancer. Established in 2012 and adopting an open access model since 2020, OncoImmunology provides a platform for high-quality research disseminated globally, with a notable focus on innovative therapies and immunotherapeutic strategies aimed at improving patient outcomes. The journal boasts an impressive impact in the field, holding Q1 rankings in both Immunology and Oncology categories for 2023, and it is recognized within the top-tier journals in its domain, reflected in its Scopus ranks and percentiles. With contributions from leading experts and a wide audience of researchers, clinicians, and advanced students, OncoImmunology not only facilitates scholarly dialogue but also addresses pivotal challenges in cancer treatment, making it an essential resource for those invested in the future of oncological and immunological research.

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, published by Mary Ann Liebert, Inc, stands out as a pivotal resource in the fields of immunology, virology, and cell biology, providing comprehensive insights into cytokine functions and their roles in immune responses. With ISSN 1079-9907 and E-ISSN 1557-7465, the journal aims to disseminate innovative research that advances our understanding of interferon and cytokine biology, a crucial aspect for developing therapeutic strategies against various diseases. Covering a broad scope of research from 1995 to 2024, it boasts a respectable impact factor within its category quartiles, ranking Q2 in Medicine (miscellaneous) and Q3 in the domains of Cell Biology, Immunology, and Virology as of 2023. While it does not provide open access options, the journal remains essential for academics, researchers, and professionals dedicated to exploring the complexities of immune signaling pathways and their implications for health and disease. The journal’s consistent contribution to scientific discourse underscores its importance in elevating query-driven studies to foster advancements in biomedical science.

Cancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.

Journal of Immunotoxicology, published by Taylor & Francis Ltd, is at the forefront of research in the intersecting fields of immunology and toxicology. With an annual impact factor that reflects its growing influence, this Open Access journal has been essential for disseminating valuable knowledge since its inception in 2004. The journal welcomes novel research articles, reviews, and commentary that explore the effects of xenobiotics on the immune system, contributing to a deeper understanding of immunotoxicological mechanisms and implications for human health. As a recognized platform, it has achieved commendable rankings in Scopus, positioning it within Q3 in Immunology and Q2 in Toxicology categories as of 2023. This ensures that the journal remains a critical resource for researchers, professionals, and students seeking to advance their knowledge and contribute to the evolving landscape of immunotoxicology. With an Open Access model since 2017, it maximizes accessibility and reaches a global audience, supporting the collaborative efforts needed to address contemporary challenges in health and safety.

International Immunopharmacology, published by Elsevier, stands as a prominent journal within the disciplines of immunology and pharmacology. With an ISSN of 1567-5769 and an E-ISSN of 1878-1705, this esteemed journal is based in the Netherlands and features a robust commitment to disseminating high-quality research from its inception in 2001 through 2024. The journal has achieved impressive rankings, securing a Q1 category in Pharmacology and Q2 in both Immunology and Immunology and Allergy as of 2023. With its strategic focus on bridging the gap between immunology and pharmacological applications, International Immunopharmacology attracts a diverse readership, including researchers, healthcare professionals, and students interested in the latest advancements in therapeutic agents and immune system modulation. Furthermore, it offers an open access option, enhancing the accessibility and reach of its invaluable content. As a pivotal resource in the field, this journal not only facilitates the exchange of innovative ideas but also fosters a deeper understanding of the complexities of immunopharmacology in today’s research landscape.

INTERNATIONAL IMMUNOLOGY, published by OXFORD UNIV PRESS, stands out as a premier journal in the field of immunology, providing a vital platform for disseminating groundbreaking research and innovative developments within the discipline. With an impressive Q1 ranking in Immunology and Allergy, as well as in Medicine (miscellaneous), it consistently showcases high-impact studies that contribute to the advancement of immunological knowledge. The journal spans over three decades, from its inception in 1989 to its ongoing contributions as of 2024, thus solidifying its reputation in the scientific community. Researchers, professionals, and students will find valuable articles that delve into the complexities of immune responses, therapeutic interventions, and emerging immunological paradigms, ensuring INTERNATIONAL IMMUNOLOGY remains at the forefront of knowledge in the life sciences.